G1 Therapeutics Inc (GTHX)
4.43
+0.30
(+7.26%)
USD |
NASDAQ |
May 02, 16:00
4.43
0.00 (0.00%)
After-Hours: 20:00
G1 Therapeutics Enterprise Value: 184.98M for May 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 01, 2024 | 184.98M |
April 30, 2024 | 166.19M |
April 29, 2024 | 163.58M |
April 26, 2024 | 177.68M |
April 25, 2024 | 170.89M |
April 24, 2024 | 177.68M |
April 23, 2024 | 188.12M |
April 22, 2024 | 183.42M |
April 19, 2024 | 183.94M |
April 18, 2024 | 187.07M |
April 17, 2024 | 192.81M |
April 16, 2024 | 182.37M |
April 15, 2024 | 194.38M |
April 12, 2024 | 206.91M |
April 11, 2024 | 213.69M |
April 10, 2024 | 212.13M |
April 09, 2024 | 224.13M |
April 08, 2024 | 218.39M |
April 05, 2024 | 218.91M |
April 04, 2024 | 207.43M |
April 03, 2024 | 215.78M |
April 02, 2024 | 209.52M |
April 01, 2024 | 206.91M |
March 28, 2024 | 194.90M |
March 27, 2024 | 202.73M |
Date | Value |
---|---|
March 26, 2024 | 193.34M |
March 25, 2024 | 185.51M |
March 22, 2024 | 178.20M |
March 21, 2024 | 162.54M |
March 20, 2024 | 149.49M |
March 19, 2024 | 140.62M |
March 18, 2024 | 136.96M |
March 15, 2024 | 131.74M |
March 14, 2024 | 132.26M |
March 13, 2024 | 150.01M |
March 12, 2024 | 142.70M |
March 11, 2024 | 151.05M |
March 08, 2024 | 159.41M |
March 07, 2024 | 156.27M |
March 06, 2024 | 153.66M |
March 05, 2024 | 154.19M |
March 04, 2024 | 160.45M |
March 01, 2024 | 164.10M |
February 29, 2024 | 142.70M |
February 28, 2024 | 143.22M |
February 27, 2024 | 94.68M |
February 26, 2024 | 89.46M |
February 23, 2024 | 84.68M |
February 22, 2024 | 81.04M |
February 21, 2024 | 81.56M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
9.835M
Minimum
Sep 25 2023
1.198B
Maximum
Sep 11 2019
367.56M
Average
328.03M
Median
Sep 21 2020
Enterprise Value Benchmarks
Amicus Therapeutics Inc | 3.180B |
Geron Corp | 1.973B |
Palatin Technologies Inc | 20.69M |
Oragenics Inc | 2.992M |
TG Therapeutics Inc | 2.330B |
Enterprise Value Related Metrics
Net Income (Quarterly) | -10.88M |
Revenue (Quarterly) | 14.87M |
Total Expenses (Quarterly) | 23.80M |
EPS Diluted (Quarterly) | -0.21 |
Gross Profit Margin (Quarterly) | 91.56% |
Profit Margin (Quarterly) | -73.14% |
Earnings Yield | -21.44% |
Normalized Earnings Yield | -21.44 |